P3 Health Partners (PIII) Revenue & Revenue Breakdown
P3 Health Partners Revenue Highlights
Latest Revenue (Y)
$1.50B
Latest Revenue (Q)
$373.23M
Main Segment (Y)
Capitated Revenue
P3 Health Partners Revenue by Period
P3 Health Partners Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $1.50B | 18.48% |
| 2023-12-31 | $1.27B | 20.66% |
| 2022-12-31 | $1.05B | -99.79% |
| 2021-12-31 | $491.06B | 101037.34% |
| 2020-12-31 | $485.54M | 233.75% |
| 2019-12-31 | $145.48M | 65.89% |
| 2018-12-31 | $87.70M | - |
P3 Health Partners generated $1.50B in revenue during NA 2024, up 18.48% compared to the previous quarter, and up 1031.37% compared to the same period a year ago.
P3 Health Partners Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $373.23M | 0.68% |
| 2024-12-31 | $370.69M | 2.36% |
| 2024-09-30 | $362.12M | -4.49% |
| 2024-06-30 | $379.16M | -2.40% |
| 2024-03-31 | $388.49M | 12.00% |
| 2023-12-31 | $346.86M | 20.29% |
| 2023-09-30 | $288.35M | -12.38% |
| 2023-06-30 | $329.09M | 8.94% |
| 2023-03-31 | $302.08M | 16.99% |
| 2022-12-31 | $258.20M | 4.00% |
| 2022-09-30 | $248.26M | -7.87% |
| 2022-06-30 | $269.45M | -1.50% |
| 2022-03-31 | $273.54M | -99.94% |
| 2021-12-31 | $490.60B | 313344.81% |
| 2021-09-30 | $156.52M | 3.37% |
| 2021-06-30 | $151.42M | 0.08% |
| 2021-03-31 | $151.30M | 16.03% |
| 2020-12-31 | $130.40M | 1.21% |
| 2020-09-30 | $128.84M | 10.25% |
| 2020-06-30 | $116.86M | 1.66% |
| 2020-03-31 | $114.96M | - |
P3 Health Partners generated $373.23M in revenue during Q1 2025, up 0.68% compared to the previous quarter, and up 107.60% compared to the same period a year ago.
P3 Health Partners Revenue Breakdown
P3 Health Partners Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| Capitated Revenue | $1.48B |
| Health Care, Patient Service | $16.85M |
Latest
P3 Health Partners's latest annual revenue breakdown by segment (product or service), as of Dec 24: Capitated Revenue (98.88%), and Health Care, Patient Service (1.12%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Dec 24 | Sep 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 |
|---|---|---|---|---|---|---|---|
| Capitated Revenue | $351.72M | $741.76M | $357.71M | $384.13M | $285.15M | $325.62M | $298.70M |
| Health Care, Patient Service | $4.06M | $8.08M | $4.42M | $4.35M | $3.47M | $3.37M | - |
| Health Care, Other | - | - | - | - | $3.20M | - | - |
| Incentive Fees | - | - | - | - | $168.00K | - | - |
Latest
P3 Health Partners's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Capitated Revenue (98.86%), and Health Care, Patient Service (1.14%).
P3 Health Partners Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PIII | P3 Health Partners | $1.50B | $373.23M |
| CASI | CASI Pharmaceuticals | $33.88M | $3.41M |
| BMGL | Basel Medical Group Ltd Ordinary Shares | $10.05M | - |
| NXGL | NEXGEL | $8.69M | $2.88M |
| SONN | Sonnet BioTherapeutics | $147.81K | - |
| APLM | Apollomics | - | - |
| IINN | Inspira Technologies Oxy B.H.N. | - | - |
| BOLD | Boundless Bio | - | - |
| KZR | Kezar Life Sciences | - | - |
| RNTX | Rein Therapeutics | - | - |